Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50

Affiliations

¹ Pulmonary Department-Oncology Unit, "Theageneio" Cancer Hospital, Thessaloniki, Greece.
² Oncology Department, University of Thessaly, Larissa, Greece.
³ Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴ Laboratory of Proteomics and Protein Sciences, Veterans Affair Health System, Baltimore, MD, USA.
⁵ Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200000, China.

Editorial

Paul Zarogoulidis et al. Transl Lung Cancer Res. 2018 Feb.

. 2018 Feb;7(Suppl 1):S28-S30.

doi: 10.21037/tlcr.2018.01.04.

¹ Pulmonary Department-Oncology Unit, "Theageneio" Cancer Hospital, Thessaloniki, Greece.
² Oncology Department, University of Thessaly, Larissa, Greece.
³ Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴ Laboratory of Proteomics and Protein Sciences, Veterans Affair Health System, Baltimore, MD, USA.
⁵ Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200000, China.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. Carbone DP, et al. N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493. N Engl J Med. 2017. PMID: 28636851 Free PMC article.

1. Haidong H, Yunye N, Wei Z, et al. Multiple guided technologies based on radial probe endobronchial ultrasound for the diagnosis of solitary peripheral pulmonary lesions: a single-center study. J Cancer 2017;8:3514-21. 10.7150/jca.20035 - DOI - PMC - PubMed
1. Oezkan F, Khan A, Zarogoulidis P, et al. Efficient utilization of EBUS-TBNA samples for both diagnosis and molecular analyses. Onco Targets Ther 2014;7:2061-5. - PMC - PubMed
1. Domvri K, Zarogoulidis P, Darwiche K, et al. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. J Cancer 2013;4:736-54. 10.7150/jca.7734 - DOI - PMC - PubMed
1. Absenger G, Terzic J, Bezan A. ASCO update: lung cancer. Memo 2017;10:224-7. 10.1007/s12254-017-0373-x - DOI - PMC - PubMed
1. Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016;27:147-53. 10.1093/annonc/mdv489 - DOI - PubMed